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Abstract
Purpose: The aim of this study was to evaluate long-term embryo
cryopreservation, utilization, and success rate in patients subjected to
gonadotoxic treatments in the context of cancer. Methods: This is a retrospective
study on patients (n = 54) undergoing ovarian stimulation and IVF for fertility
preservation between January 1997 and June 2014. Embryos were slow-frozen
and stored until the women were cured and able to undergo embryo transfer.
Results: Fifty-four women underwent 66 oocyte pick-up procedures in total, and
embryos were obtained from 52 of the 54 patients. Four patients died before their
frozen embryos could be thawed. Of the remaining 48, 9 women returned to use
their embryos, resulting in 6 pregnancies (66 % cumulative pregnancy rate), two
of which ended in miscarriage. The live birth rate per patient was thus 44 % (4/9).
The true come-back rate, calculated after applicable exclusions, was found to be
23 %. Conclusion: IVF followed by embryo freezing is a widely estab...
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Abstract
Purpose The aim of this study was to evaluate long-term em-
bryo cryopreservation, utilization, and success rate in patients
subjected to gonadotoxic treatments in the context of cancer.
Methods This is a retrospective study on patients (n=54) un-
dergoing ovarian stimulation and IVF for fertility preservation
between January 1997 and June 2014. Embryos were slow-
frozen and stored until the women were cured and able to
undergo embryo transfer.
Results Fifty-four women underwent 66 oocyte pick-up pro-
cedures in total, and embryos were obtained from 52 of the 54
patients. Four patients died before their frozen embryos could
be thawed. Of the remaining 48, 9 women returned to use their
embryos, resulting in 6 pregnancies (66 % cumulative preg-
nancy rate), two of which ended in miscarriage. The live birth
rate per patient was thus 44 % (4/9). The true come-back rate,
calculated after applicable exclusions, was found to be 23 %.
Conclusion IVF followed by embryo freezing is a widely
established technique for fertility preservation, but little has
been published on the outcomes in cancer patients. While we
found the number of good-quality embryos to be lower than in
a normal population, the cumulative live birth rate was similar
to that achieved with fresh embryos in non-cancer patients.
The utilization rate of this fertility preservation method can be
considered high.
Keywords IVF . Cancer patients . Embryo banking . Fertility
preservation . Cryopreservation . Utilization rate . Thawing
Introduction
With recent advances in cancer treatments, the number of young
cancer survivors with impaired fertility is growing. The quality
of life of these patients may be severely impaired if fertility
preservation options are not discussed prior to treatment [1].
Women having to undergo gonadotoxic treatments have
several options to preserve their fertility and enable them to
conceive when they have recovered: embryo cryopreserva-
tion, oocyte cryopreservation, and ovarian tissue cryopreser-
vation. Currently, embryo and mature oocyte cryopreservation
are the only methods endorsed by the American Society for
Reproductive Medicine (ASRM) Committee [2]. While ovar-
ian tissue cryopreservation is the only option available for
young prepubertal patients and those needing to start chemo-
therapy right away, if there is time for ovarian stimulation and
the patient has a partner, embryo cryopreservation should be
proposed.
As a widely established technique, embryo cryopreservation
has reliable success rates [3]. Moreover, frozen embryo transfer
has been found to yield significantly higher ongoing and clinical
pregnancy rates than fresh embryo transfer, which could be
explained by superior embryo-endometrium synchrony [3, 4].
On the other hand, there is still some controversy
concerning the impact of cancer or systemic diseases on the
number and/or quality of oocytes retrieved from these
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patients. The ovarian response to stimulation in cancer pa-
tients may be poorer than expected [5–7], but this remains a
matter of debate, as Tulandi and Holzer [8] found that malig-
nancies do not affect oocyte numbers.
Very little has been published on the efficacy and utilization
rates of long-term embryo cryopreservation in cancer patients
[9–11].
In the light of this growing interest in fertility preservation
and restoration, the aim of our study was to evaluate the suc-
cess of the technique and review utilization and pregnancy
rates after IVF and long-term embryo cryopreservation prior
to gonadotoxic treatment.
Patients and methods
Patients
A retrospective study was conducted on patients undergoing
IVF cycles between January 1997 and June 2014. During this
period, 54 women underwent ovarian stimulation and IVF for
fertility preservation, resulting in 66 oocyte pick-up proce-
dures. Patient age at the time of oocyte retrieval ranged from
21 to 41 years (mean 30±4.6 years).
Patients gave their informed consent for their medical and
administrative data to be communicated to external bodies in a
coded manner. Data were analyzed retrospectively from med-
ical files and our internal computerized laboratory database,
developed to ensure quality control assessment and compari-
son on a national level.
Ovarian stimulation
The type of stimulation administered depended on the patient
cycle phase at the time of referral. Before 2012, patients in the
follicular phase received a short agonist or antagonist proto-
col, while those in the luteal phase received a long agonist
protocol. However, the majority of patients were taking oral
contraceptives and they all underwent a short protocol after
discontinuation of the pill. Since February 2012, all patients
have undergone random start stimulation (n=14).
Twenty-eight cycles were downregulated with GnRH ago-
nists and 38 with GnRH antagonists (Orgalutran®, Organon,
Oss, the Netherlands, or Cetrotide® Merck-Serono, Darm-
stadt, Germany). Gonadotropins used were recombinant
(Gonal-F®, Merck-Serono, and Purégon®, MSD, Darmstadt,
Germany,) or urinary purified (Menopur®, Ferring, Kiel, Ger-
many). Trigger was performed by subcutaneous injection of
human chorionic gonadotropin (hCG) (Pregnyl®, Shering-
Plough) when the dominant follicle reached at least 15–
16 mm in size. The patients suffering from breast cancer did
not receive any specific treatment as aromatase inhibitors.
In vitro fertilization and embryo cryopreservation
Fertilization was mostly achieved by intracytoplasmic sperm
injection (ICSI) to avoid the risk of non-fertilization, except in
3 cycles. All embryos were frozen on day 2 or 3 (slow-freez-
ing protocol using a programmable freezer), depending on the
day of pick-up. Slow freezing was performed according to the
protocol described by Van Langendonckt et al. [12], with the
use of Freeze-Kit1™ (Vitrolife, Sweden).
Thawing cycles
Estrogen replacement therapy (Progynova, Bayer Schering,
Berkshire, UK), 4 to 6 mg daily, was administered to patients
for a minimum of 14 days. Luteal support with progesterone
(Utrogestan, Goodlife Pharma, Leylstad, the Netherlands) was
initiated when endometrial thickness was at least 8 mm and,
respectively, 2 or 3 days before embryo transfer depending on
whether embryos had been frozen on day 2 or 3. A maximum
of two thawed embryos were transferred.
Results
Patients
During the study period, 54 patients underwent 66 oocyte
pick-up procedures, yielding embryos for cryopreservation
in all but 2 (Fig. 1). Fifty-two patients were referred for neo-
plastic pathologies and two for non-neoplastic conditions
Patients undergoing cycle 
stimulation for fertility 
preservation: n=54
Patients who died
before their embryos 
could be thawed: n=4 Patients who returned for 
thawing: n=9
Patients achieving live birth: n=4
(LBR per transfer: 4/20 (20 %))
Patients suffering early  
miscarriage (<12 weeks):
n=2
Patients achieving alive  
birth:  n=4
Patients who have not  
yet returned: n=39
Patients with no 
embryos for 
cryopreservation: n=2
Patients with embryos
for cryopreservation: 
n=52
Patients who are 
still alive: n = 48 
Patients presenting pregnancy: n=6
(CPR per patient: 66 %)
(PR per transfer: 7/20 (35 %)
Fig 1 Utilization rates and pregnancy outcomes per patient undergoing
stimulation for fertility preservation. CPR cumulative pregnancy rate, PR
pregnancy rate, LBR live birth rate
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(scleroderma and sarcoidosis). The most frequent oncological
indications were lymphoma (n=18) (13 Hodgkin’s lymphoma
and 5 non-Hodgkin lymphoma) and breast cancer (n=12),
followed by borderline ovarian tumors (BOT, n=8) and colo-
rectal cancer (n=7). Other pathologies included sarcoma (n=
2), ovarian (n=1) or cervical (n=1) cancer, medullar aplasia
(n=1), chronic leukemia (n=1), and pseudomyxoma (n=1).
In the woman with ovarian cancer (stage II), one IVF attempt
was approved after unilateral adnexectomy, before chemother-
apy and debulking surgery were initiated.
When possible, more than one stimulation cycle was au-
thorized, so 10 patients were able to undergo 2–3 cryopreser-
vation cycles, 6 of them presenting with BOT.
Stimulation and cryopreservation
There was never a delay in cancer treatment due to ovarian
stimulation, as oncologists only referred patients whose treat-
ment and prognosis would not be affected by waiting 3 weeks
before starting chemotherapy.
For stimulation cycles, antagonist protocols with rec-FSH
were preferentially used (n=37), followed by GnRH agonist
protocols with urinary FSH (n=23) or rec-FSH (n=5), and
one cycle with GnRH antagonist and urinary FSH. The mean
total dose of gonadotropins used was 2997±1707 IU. The
estradiol level at the time of hCG trigger reached a median
of 788 pg/ml, with a range from 94 to 8019 pg/ml (Table 1).
The number of oocytes retrieved per cycle ranged from 1 to
32, with a mean of 9.66 (±7.55). The fertilization rate was
66.4 %, and the mean number of stored embryos per patient
was 4.06 (±3.68), with a range from 0 to 17 (Table 1).
Thawing
Four patients died before their embryos could be thawed
(Fig. 1). Of the remaining 48 patients, 9 have had their em-
bryos thawed, while 39 have not yet returned. This yields a
Bcome-back rate^ or embryo utilization rate of 9/48 (18.75 %).
The characteristics of patients who underwent embryo
thawing are presented in Table 2. Of the 9 patients who did
return, 5 underwent 2 cycles of ovarian stimulation and pick-
up and 4 only 1 cycle.
Altogether, 20 embryo transfers were performed, with a
total of 33 embryos. Of these 20 embryo transfers, 4 involved
use of poor-quality embryos. Seven gestational sacs were ob-
served at ultrasound, with a pregnancy rate per transfer of
35 % (7/20) and an implantation rate of 21 % (7/33). All those
who conceived had at least one intermediate-quality embryo,
except one woman who had only poor-quality embryos and
later suffered a miscarriage.
Among the 9 patients who came back, 6 pregnancies oc-
curred: 5 singleton and 1 twin (cumulative pregnancy rate per
patient 66 %). Two ended in early miscarriage, while 4 culmi-
nated in live births.
Two of these 9 patients still have embryos frozen.
Discussion
According to the latest ASRM Ethics Committee guidelines,
the most effective strategy for fertility preservation in women
is to undergo IVF and create embryos for later use [13]. Oo-
cyte vitrification is also considered a viable option [14], as the
ASRM no longer regards this technique as experimental.
Although IVF and embryo freezing are widely applied in
infertile patients, very little has been published on embryo
utilization rates and results in terms of efficacy of this tech-
nique in a cancer population.
Here, we present a series of 54 patients who underwent
ovarian stimulation and embryo cryopreservation for fertility
preservation purposes between 1997 and 2014.
Utilization rate
Of the 52 patients who had their embryos frozen, 9 have so far
come back for thawing (17 %). As 4 patients died before they
were able to return, this yields a come-back rate or embryo
utilization rate of 18.75 % (9/48). However, this figure is
slightly misleading. Indeed, patients who are treated for can-
cer are frequently advised not to conceive before they are in
remission, so we did not expect women who have had their
embryos cryopreserved in the last 2 years to return for thawing
so soon (9 patients). Hence, if we exclude these patients, the
come-back rate is actually 23 % (9/39).
When we compare our data with the literature, this more
realistic figure of 23 % is in accordance with the results of
Robertson et al. [9], who found that 26 % of patients (10/38)
returned for embryo transfer. Very recently, Cardozo et al. also
published their data on IVF outcomes of cancer patients un-
dergoing fertility preservation, covering exactly the same 17-
year period (1997–2014) as in our study [11]. They obtained a
Table 1 Stimulation results
Number of cycles 66
Gonadotropin dose (IU) (mean±SD)a 2997±1707
E2 (pg/ml) on day of hCG (median)b 788 (range 94–8019)
Number of retrieved oocytes per
cycle (mean)c
9.66 (±7.55) (range 1–32)
Fertilization rate 66.4 %
Number of stored embryos (mean±SD) 4.06±3.68 (range 0–17)
a Complete information for 63 cycles
b Complete information for 65 cycles
c Complete information for 64 cycles
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relative high utilization rate, as 21/63 (33 %) patients returned
for frozen embryo transfer. These return rates are much higher
than for sperm banking or ovarian tissue cryobanking. For
male fertility restoration, the utilization rate by cancer survi-
vors who banked sperm prior to cancer treatment is curiously
less than 10 % [15]. For cryopreserved ovarian tissue, the uti-
lization rate was calculated to be 2.3 % in 2012 [16] but the
number of patients undergoing ovarian tissue transplantation is
increasing all the time as these women decide to attempt preg-
nancy. The latest figures for 2015 show the rate to be 3.5–8 %.
Number of oocytes and embryos
The mean number of stored embryos per patient in this
study was 4.06 (±3.68), apparently similar to a control
group in one of our previous studies during the same peri-
od [17]. In this control group, the mean number of good-
quality frozen embryos obtained per patient on day 3 was
4.4, compared to 4.06 in the present study. In the latter,
however, all embryos were frozen and only 63 % of them
were of good quality, yielding an average of 2.3 good-
quality embryos per patient. We can thus confirm that even
if the mean number of stored embryos was a respectable
4.06 in the present study, their quality may possibly be
lower than in a normal population. Nevertheless, it does
not appear to impact on the cumulative live birth rate
(LBR). In a systematic review and meta-analysis, Friedler
et al. concluded that women with malignant disease should
expect a smaller number of oocytes to be retrieved after
controlled ovarian hyperstimulation for fertility preserva-
tion, compared with healthy age-matched patients [9].
However, Devesa et al. recently published that ovarian re-
sponse to stimulation in women with cancer is as expected
according to age [18]. This is still a matter of debate and
largely depends on the type of cancer and other factors,
which may constitute a bias.
Pregnancy rate
In this series of women with cancer, we report a cumulative
pregnancy rate of 66 % per patient. Indeed, of the nine patients
who came back for thawing, six conceived. This can be consid-
ered a success, as the cumulative LBR per patient was 44 %
(4/9).
For comparative purposes, we can express this figure in
LBR per transfer, which yields a rate of 20 % (4/20). In our
department in 2012, the LBR per transfer with fresh embryos
in non-cancer patients was 22.7 %, thus not significantly
different.
Although in our study the LBR is similar with frozen em-
bryos from cancer patients and fresh embryos from non-
cancer patients, there is still some controversy in the literature
regarding the quality of embryos obtained after ovarian stim-
ulation in women with cancer.
Indeed, Sabatini et al. [10] reported in 2011 a lower LBR
after transfer of frozen embryos in cancer patients compared to
women who underwent fresh embryo transfer in their depart-
ment (LBR 35 %). However, their study published in 2015 on
a series of 57 cancer patients who had embryos cryopreserved,
showed a similar LBR per transfer between cancer patients
and controls [11]. Hence, even if several other studies have
reported lower numbers of retrieved oocytes compared to con-
trols [5, 7, 19, 20], this does not appear to have any impact on
the pregnancy rate once the patient is cured [11, 21].
Some patients may benefit from more than one cycle and
have more embryos cryopreserved, thereby enhancing their
chances of becoming pregnant. Use of GnRH antagonists
can also shorten the interval from oocyte retrieval to the next
menses, and this in turn improves the likehood of multiple
back-to-back cycles before initiating cancer treatment [22].
We believe this is a very important consideration for these
patients, who want to do all they can to maximize their
chances of pregnancy.
Table 2 Characteristics of patients undergoing embryo thawing
Pathology Age at
freezing
Number of
stimulation cycles
Number of
frozen embryos
Number of
thawed embryos
Number of
transferred embryos
Pregnancy
Breast cancer 34 1 17 1 1 Live birth
Breast cancer 34 1 4 4 3 Live birth
Breast cancer 41 2 3 3 3 Early miscarriage
BOT 25 2 14 14 10 Early miscarriage
BOT 36 2 6 2 2 Live birth
Ovarian cancer 26 1 4 4 4 Live birth (twins)
BOT 30 2 3 3 3 No
Rectal adenocarcinoma 34 1 8 8 6 No
Colon adenocarcinoma 35 2 2 2 1 No
Total / 14 61 41 33 6+/9
BOT borderline ovarian tumor
1236 J Assist Reprod Genet (2015) 32:1233–1237
Conclusions and perspectives
This study shows that utilization rates of long-term cryopre-
served embryos are relatively high (almost one in four) and
that outcomes in terms of pregnancy rates are at least as good
as those in the general population.
However, there are some limitations to performing oocyte
or embryo cryopreservation in cancer patients. Studies by
Rienzi et al. and Cobo et al. show that around 20 oocytes are
required to achieve a live birth [23, 24]. This number can be
obtained in egg donation programs or in case of fertility pres-
ervation for social reasons, but rarely in women with cancer.
Even when a delay in treatment is possible, it is usually for no
more than one cycle [24, 25]. Thus, the good results obtained
in egg donation programs cannot be extrapolated to cancer
patients, nor can the quality of eggs be guaranteed in these
women [24, 26]. This is why, in a recent paper, we proposed a
combined approach, cryopreservation of ovarian cortex
followed by controlled ovarian stimulation and oocyte pick-
up, if treatment can be delayed. Combining these two different
methods of fertility preservation is a valuable strategy to max-
imize the future fertility potential of our cancer patients [18].
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